2025 State of Regulatory Operations: Industry Benchmarks and Trends

2025 State of Regulatory Operations: Industry Benchmarks and Trends

The regulatory operations landscape is undergoing a period of significant transition. Organizational demands are increasing, technology adoption is uneven, and the gap between leading and lagging organizations is widening. This executive summary captures the key trends, benchmarks, and emerging patterns that defined regulatory operations in 2025 — and that will shape the function through 2026 and beyond.

1. Resource Constraints Are the Defining Challenge

Regulatory operations teams across the industry are being asked to support expanding portfolios, more complex filing strategies, and increasing regulatory scrutiny — without proportional growth in headcount. Industry surveys consistently show that over 60% of regulatory operations leaders cite staffing as their top constraint, ahead of budget and technology.

The arithmetic is straightforward. A mid-size biotech with three to five active INDs and one or two marketed products may have a regulatory operations team of four to eight people. That same team is now expected to manage global submissions across ten or more markets, respond to an increasing volume of agency queries, and prepare for format changes — all while maintaining the baseline publishing cadence.

The result is a function operating at or near capacity, with limited bandwidth for process improvement, technology evaluation, or strategic initiatives. Organizations report that senior publishing specialists spend an estimated 40% of their time on tasks that are rules-based and repetitive, including manual hyperlink validation, PDF formatting checks, and folder structure assembly. This represents a significant misallocation of experienced talent.

2. The Technology Adoption Gap

Despite two decades of digital transformation in adjacent functions — clinical operations, pharmacovigilance, medical affairs — regulatory operations remains one of the least technologically mature functions in the pharmaceutical enterprise.

The majority of organizations still rely on desktop-based publishing tools installed on local machines or on-premise servers. Manual QC checklists remain the primary quality gate for most submissions. Integration between publishing tools, document management systems, and regulatory information management platforms is limited or nonexistent in roughly 70% of organizations surveyed.

Organizations report spending 20 to 30 hours per submission on manual hyperlink validation alone. End-to-end QC processes — from document formatting through final technical validation — account for 35 to 50% of total publishing cycle time. These benchmarks have remained largely unchanged over the past five years, suggesting that process documentation without automation has reached its ceiling of effectiveness.

3. Cost Pressure on Mid-Size Organizations

The enterprise RIM market has consolidated around a small number of large platforms with price points and implementation timelines designed for top-20 pharma companies. For mid-size biotechs — companies with annual revenues between $500 million and $5 billion — the total cost of ownership for a full-featured RIM platform, including licensing, implementation, validation, and ongoing maintenance, can exceed $2 million in the first year alone.

This creates a structural disadvantage. Mid-size companies often have regulatory complexity approaching that of larger organizations but lack the budget to deploy the same tooling. The result is a reliance on point solutions, spreadsheet-based tracking, and manual processes that are increasingly inadequate for the volume and complexity of work required.

The market is beginning to respond. Cloud-native platforms with modular pricing and faster implementation timelines are emerging as alternatives to the monolithic enterprise RIM model. Early adopters in the mid-size segment report 50 to 60% reductions in total cost of ownership compared to traditional on-premise deployments.

4. eCTD 4.0 Readiness Remains Low

Despite years of industry discussion, fewer than 15% of organizations report having an active eCTD 4.0 readiness program in place. The majority — approximately 65% — describe their readiness status as “monitoring but not acting.” The remaining 20% report having no formal readiness assessment underway.

The challenge is partly structural. eCTD 4.0 represents a move from document-centric to data-centric submissions, which has implications far beyond the publishing tool. Authoring processes, content management practices, metadata governance, and internal training all require evaluation and potential redesign.

Organizations that have begun preparation cite three primary activities: vendor readiness assessments, internal gap analyses of current metadata practices, and pilot programs with select submission types. The consensus view is that full industry transition will take three to five years beyond initial regulatory mandates, creating an extended period of dual-format support that will further strain operational resources.

5. AI Adoption: High Interest, Low Implementation

Interest in applying artificial intelligence to regulatory operations is near universal. Actual deployment is not. Approximately 80% of regulatory operations leaders report exploring AI use cases, but fewer than 20% have deployed AI capabilities in production workflows.

Where AI has been implemented, use cases cluster in a narrow range: document search and retrieval, basic classification and tagging, and template-based content generation. More advanced applications — automated QC, intelligent submission planning, predictive analytics for review timelines — remain largely aspirational.

The primary barriers cited are data readiness (unstructured content, inconsistent metadata), validation concerns (how to qualify AI-assisted processes in a GxP environment), and integration limitations (AI tools that do not connect with existing publishing and document management systems).

Organizations that have moved beyond pilot programs share a common characteristic: they invested in data governance and system integration before deploying AI capabilities, rather than attempting to apply intelligence on top of fragmented data.

6. CRO Dependency Creates Integration Challenges

Outsourcing of regulatory operations activities — particularly publishing, formatting, and regional submissions — continues to increase. An estimated 45% of submission publishing volume across the industry is now performed by CROs or contract publishing providers.

This trend brings operational benefits but introduces persistent challenges. Organizations report that CRO onboarding for a new publishing engagement takes an average of four to six weeks, driven largely by technology provisioning, access configuration, and process alignment. Quality variability between CRO teams requires additional internal oversight. And the lack of shared platforms means that work products must be transferred, re-validated, and reconciled — adding cycle time and error risk.

The most effective CRO collaboration models reported in 2025 share a common feature: a shared cloud-based workspace where both internal and external teams operate within the same system, using the same templates, the same validation rules, and the same review workflows. This approach reduces onboarding time to days rather than weeks and eliminates the reconciliation overhead of file-based handoffs.

7. The Emerging Standard: Integrated, Cloud-Native Platforms

Across all of these trends, a pattern is emerging. The organizations making the most measurable progress in operational efficiency, cost management, and strategic capability share a technology profile: cloud-native platforms that integrate publishing, review, and planning in a single environment.

Key attributes of this emerging standard include:

• Continuous validation — QC runs in real time as content is assembled, not as a separate phase after publishing is complete.
• Built-in collaboration — review and approval workflows are native to the platform, eliminating email-based review cycles.
• Modular deployment — organizations can adopt capabilities incrementally rather than committing to a multi-year enterprise implementation.
• API-first architecture — integration with document management, RIM, and clinical systems is enabled by design, not as a custom development effort.
• CRO-ready access models — external partners can be provisioned in hours with role-based permissions and full audit trails.

DnXT’s Perspective

At DnXT, these benchmarks and trends confirm what we hear from regulatory operations leaders every day: the current model is not sustainable, and incremental improvements to legacy infrastructure will not close the gap.

Our view is that the industry is at an inflection point. The organizations that invest now in modern, integrated regulatory operations platforms will compound their advantage over the next three to five years — in speed, in cost efficiency, in data quality, and in their ability to attract and retain regulatory talent that refuses to spend careers on manual processes.

The 2025 data tells a clear story. The question for every regulatory operations leader is what they intend to do about it in 2026.